This content is machine translated Swiss Society of Cardiology Joint Annual Meeting 2018, Basel Advances in atherosclerosis therapy The PCSK9 inhibitors evolocumab and alirocumab can be used successfully to lower LDL cholesterol, as shown by large outcome studies. Whether anti-inflammation can also prophylactically reduce cardiovascular risk has been…
View Post 8 min This content is machine translated Cholesterol Management Impressive results of PCSK9 inhibitors Cholesterol management was the subject of discussion at the Prevention Summit at the University Hospital Zurich. The new lipid guidelines from the AHA/ACC are generating a lot of criticism. This…
